US7620500B2 - Optimization of crossover points for directed evolution - Google Patents

Optimization of crossover points for directed evolution Download PDF

Info

Publication number
US7620500B2
US7620500B2 US10/386,903 US38690303A US7620500B2 US 7620500 B2 US7620500 B2 US 7620500B2 US 38690303 A US38690303 A US 38690303A US 7620500 B2 US7620500 B2 US 7620500B2
Authority
US
United States
Prior art keywords
sequence
crossover
crossover point
chimeric
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US10/386,903
Other languages
English (en)
Other versions
US20030198988A1 (en
Inventor
Emily C. Mundorff
Sridhar Govindarajan
Claes Gustafsson
Jeremy S. Minshull
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Codexis Inc
Original Assignee
Maxygen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Inc filed Critical Maxygen Inc
Priority to US10/386,903 priority Critical patent/US7620500B2/en
Assigned to MAXYGEN, INC. reassignment MAXYGEN, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GOVINDARAJAN, SRIDHAR, MINSHULL, JEREMY S., MUNDORFF, EMILY C., GUSTAFSSON, CLAES
Publication of US20030198988A1 publication Critical patent/US20030198988A1/en
Priority to US11/818,237 priority patent/US8224580B2/en
Priority to US12/557,434 priority patent/US8108150B2/en
Publication of US7620500B2 publication Critical patent/US7620500B2/en
Application granted granted Critical
Assigned to CODEXIS MAYFLOWER HOLDINGS, LLC reassignment CODEXIS MAYFLOWER HOLDINGS, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MAXYGEN, INC.
Assigned to CODEXIS, INC. reassignment CODEXIS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CODEXIS MAYFLOWER HOLDINGS, LLC
Assigned to INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT reassignment INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CODEXIS, INC.
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G16B35/20—Screening of libraries
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
US10/386,903 2002-03-09 2003-03-10 Optimization of crossover points for directed evolution Active 2025-06-25 US7620500B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/386,903 US7620500B2 (en) 2002-03-09 2003-03-10 Optimization of crossover points for directed evolution
US11/818,237 US8224580B2 (en) 2002-03-09 2007-06-12 Optimization of crossover points for directed evolution
US12/557,434 US8108150B2 (en) 2002-03-09 2009-09-10 Optimization of crossover points for directed evolution

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36350502P 2002-03-09 2002-03-09
US37359102P 2002-04-18 2002-04-18
US10/386,903 US7620500B2 (en) 2002-03-09 2003-03-10 Optimization of crossover points for directed evolution

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/818,237 Division US8224580B2 (en) 2002-03-09 2007-06-12 Optimization of crossover points for directed evolution
US12/557,434 Continuation US8108150B2 (en) 2002-03-09 2009-09-10 Optimization of crossover points for directed evolution

Publications (2)

Publication Number Publication Date
US20030198988A1 US20030198988A1 (en) 2003-10-23
US7620500B2 true US7620500B2 (en) 2009-11-17

Family

ID=28045308

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/386,903 Active 2025-06-25 US7620500B2 (en) 2002-03-09 2003-03-10 Optimization of crossover points for directed evolution
US11/818,237 Expired - Fee Related US8224580B2 (en) 2002-03-09 2007-06-12 Optimization of crossover points for directed evolution
US12/557,434 Expired - Fee Related US8108150B2 (en) 2002-03-09 2009-09-10 Optimization of crossover points for directed evolution

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/818,237 Expired - Fee Related US8224580B2 (en) 2002-03-09 2007-06-12 Optimization of crossover points for directed evolution
US12/557,434 Expired - Fee Related US8108150B2 (en) 2002-03-09 2009-09-10 Optimization of crossover points for directed evolution

Country Status (5)

Country Link
US (3) US7620500B2 (fr)
EP (1) EP1488335A4 (fr)
JP (3) JP4851687B2 (fr)
AU (1) AU2003213846A1 (fr)
WO (1) WO2003078583A2 (fr)

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080020397A1 (en) * 2002-03-09 2008-01-24 Maxygen, Inc. Optimization of crossover points for directed evolution
WO2012024698A1 (fr) 2010-08-20 2012-02-23 Codexis, Inc. Utilisation de protéines de la famille 61 des glycoside hydrolases dans le traitement de la cellulose
WO2013028701A1 (fr) 2011-08-22 2013-02-28 Codexis, Inc. Variants protéiques des glycosides hydrolases gh61 et cofacteurs renforçant l'activité des gh61
WO2013188305A2 (fr) 2012-06-11 2013-12-19 Codexis, Inc. Variants de la beta-xylosidase fongique
US8663962B2 (en) 2011-03-30 2014-03-04 Codexis, Inc. Pentose fermentation by a recombinant microorganism
US8778652B2 (en) 2011-06-30 2014-07-15 Codexis, Inc. Pentose fermentation by a recombinant microorganism
WO2014172541A2 (fr) 2013-04-18 2014-10-23 Codexis, Inc. Polypeptides de phénylalanine ammoniac-lyase modifiés
WO2015073555A1 (fr) 2013-11-13 2015-05-21 Codexis, Inc. Imines réductases manipulées et procédés d'amination réductrice de composés cétoniques et aminés
WO2015161019A1 (fr) 2014-04-16 2015-10-22 Codexis, Inc. Tyrosine ammonia-lyase génétiquement modifiée
US9322027B2 (en) 2010-08-20 2016-04-26 Shell Oil Company Expression constructs comprising fungal promoters
WO2016085916A1 (fr) 2014-11-25 2016-06-02 Codexis, Inc. Imines réductases génétiquement modifiées et procédés d'amination réductrice de composés cétoniques et aminés
WO2016105889A1 (fr) 2014-12-22 2016-06-30 Codexis, Inc. Variants d'alpha-galactosidase humaine
WO2016130412A1 (fr) 2015-02-10 2016-08-18 Codexis, Inc. Polypeptides de cétoréductase pour la synthèse de composés chiraux
US9434919B2 (en) 2011-09-30 2016-09-06 Codexis, Inc. Fungal proteases
WO2016179464A1 (fr) 2015-05-07 2016-11-10 Codexis, Inc. Pénicilline g acylases
WO2017007547A1 (fr) 2015-07-07 2017-01-12 Codexis, Inc. Nouveaux variants de p450-bm3 ayant une activité améliorée
US9611515B2 (en) 2012-11-20 2017-04-04 Codexis, Inc. Pentose fermentation by a recombinant microorganism
US9611462B2 (en) 2011-12-20 2017-04-04 Codexis, Inc. Endoglucanase 1B (EG1B) variants
US9708587B2 (en) 2014-07-09 2017-07-18 Codexis, Inc. P450-BM3 variants with improved activity
WO2017193022A1 (fr) 2016-05-05 2017-11-09 Codexis, Inc. Pénicilline g acylases
WO2017213758A1 (fr) 2016-06-09 2017-12-14 Codexis, Inc. Biocatalyseurs et procédés d'hydroxylation de composés chimiques
WO2018038906A1 (fr) 2016-08-26 2018-03-01 Codexis, Inc. Imines réductases manipulées et procédés d'amination réductrice de composés cétoniques et aminés
WO2018144679A2 (fr) 2017-02-03 2018-08-09 Codexis, Inc. Glycosyl transférases modifiées et procédés de glucosylation de glycosides de stéviol
WO2018208665A1 (fr) 2017-05-08 2018-11-15 Codexis, Inc. Variants de ligase modifiés
EP3418929A1 (fr) 2013-09-27 2018-12-26 Codexis, Inc. Sélection automatique de variantes enzymatiques
US10738286B2 (en) 2017-06-30 2020-08-11 Codexis, Inc. T7 RNA polymerase variants
US10745681B2 (en) 2017-01-05 2020-08-18 Codexis, Inc. Penicillin-G acylases
US10793841B2 (en) 2017-06-30 2020-10-06 Codexis, Inc. T7 RNA polymerase variants
US10889806B2 (en) 2018-07-09 2021-01-12 Codexis, Inc. Engineered pantothenate kinase variant enzymes
US10900055B2 (en) 2018-06-12 2021-01-26 Codexis, Inc. Engineered tyrosine ammonia lyase
US10995329B2 (en) 2017-02-13 2021-05-04 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
US11015180B2 (en) 2017-12-13 2021-05-25 Codexis, Inc. Carboxyesterase polypeptides for amide coupling
US11021729B2 (en) 2017-04-27 2021-06-01 Codexis, Inc. Ketoreductase polypeptides and polynucleotides
US11034948B2 (en) 2018-07-09 2021-06-15 Codexis, Inc. Engineered phosphopentomutase variant enzymes
US11060075B2 (en) 2018-10-29 2021-07-13 Codexis, Inc. Engineered DNA polymerase variants
US11162105B2 (en) 2018-07-09 2021-11-02 Codexis, Inc. Engineered purine nucleoside phosphorylase variant enzymes
US11198861B2 (en) 2018-07-12 2021-12-14 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
US11274286B2 (en) 2018-07-09 2022-03-15 Codexis, Inc. Engineered deoxyribose-phosphate aldolases
US11299723B2 (en) 2016-06-15 2022-04-12 Codexis, Inc. Engineered beta-glucosidases and glucosylation methods
US11319531B2 (en) 2017-11-07 2022-05-03 Codexis, Inc. Transglutaminase variants
US11359183B2 (en) 2017-06-14 2022-06-14 Codexis, Inc. Engineered transaminase polypeptides for industrial biocatalysis
US11427813B2 (en) 2018-12-20 2022-08-30 Codexis, Inc. Human alpha-galactosidase variants
WO2022212824A1 (fr) 2021-04-02 2022-10-06 Codexis, Inc. Enzymes variants de d'adénylate kinase modifiées
WO2022212828A1 (fr) 2021-04-02 2022-10-06 Codexis, Inc. Enzymes variantes de guanylate kinase modifiées
WO2022212832A1 (fr) 2021-04-02 2022-10-06 Codexis, Inc. Enzymes variantes de la gmp-amp synthase (cgaz) cyclique génétiquement modifiées
WO2022212835A1 (fr) 2021-04-02 2022-10-06 Codexis, Inc. Enzymes variantes d'acétate kinase modifiées
US11466259B2 (en) 2018-07-09 2022-10-11 Codexis, Inc. Engineered galactose oxidase variant enzymes
US11473077B2 (en) 2018-12-14 2022-10-18 Codexis, Inc. Engineered tyrosine ammonia lyase
US11643642B2 (en) 2017-06-27 2023-05-09 Codexis, Inc. Penicillin-g acylases
US11760981B2 (en) 2018-07-30 2023-09-19 Codexis, Inc. Engineered glycosyltransferases and steviol glycoside glucosylation methods
US11767519B2 (en) 2020-08-28 2023-09-26 Codexis, Inc. Engineered amylase variants
US11788071B2 (en) 2020-04-10 2023-10-17 Codexis, Inc. Engineered transaminase polypeptides
US11898174B2 (en) 2020-12-18 2024-02-13 Codexis, Inc. Engineered uridine phosphorylase variant enzymes
WO2024040020A1 (fr) 2022-08-15 2024-02-22 Absci Corporation Enrichissement de cellule spécifique à une activité d'affinité quantitative
US11959108B2 (en) 2020-08-28 2024-04-16 Codexis, Inc. Engineered protease variants
US11970722B2 (en) 2019-12-20 2024-04-30 Codexis, Inc. Engineered acid alpha-glucosidase variants

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX358497B (es) * 2012-03-20 2018-08-23 Sarepta Therapeutics Inc Conjugados de acido boronico de analogos de nucleotido.
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5741691A (en) 1996-01-23 1998-04-21 California Institute Of Technology Para-nitrobenzyl esterases with enhanced activity in aqueous and nonaqueous media
US6107073A (en) 1996-03-19 2000-08-22 Leukosite, Inc. Kinase capable of site-specific phosphorylation of IκBα
US6109776A (en) 1998-04-21 2000-08-29 Gene Logic, Inc. Method and system for computationally identifying clusters within a set of sequences
WO2001075767A2 (fr) 2000-03-30 2001-10-11 Maxygen, Inc. Selection de sites de recombinaison par enjambement in silico
US6323030B1 (en) 1994-02-17 2001-11-27 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
WO2001090346A2 (fr) 2000-05-23 2001-11-29 California Institute Of Technology Recombinaison de genes et mise au point de proteines hybrides
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
US6518065B1 (en) 1994-02-17 2003-02-11 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US20030032059A1 (en) 2000-05-23 2003-02-13 Zhen-Gang Wang Gene recombination and hybrid protein development

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
WO1998031837A1 (fr) 1997-01-17 1998-07-23 Maxygen, Inc. Evolution de cellules entieres et d'organismes par recombinaison recursive de sequences
DE69840382D1 (de) 1997-03-18 2009-02-05 Novozymes As Methode zur herstellung einer bibliothek mittels dna-shuffling
WO1998041653A1 (fr) 1997-03-18 1998-09-24 Novo Nordisk A/S Methode de constitution in vitro de bibliotheque d'adn
US5948653A (en) 1997-03-21 1999-09-07 Pati; Sushma Sequence alterations using homologous recombination
US6153410A (en) 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
US6399383B1 (en) 1997-10-28 2002-06-04 Maxygen, Inc. Human papilloma virus vectors
EP1030861A4 (fr) 1997-10-31 2001-09-05 Maxygen Inc Modification du tropisme viral et de la diversite d'especes hote par recombinaison du genome viral
US6537746B2 (en) 1997-12-08 2003-03-25 Maxygen, Inc. Method for creating polynucleotide and polypeptide sequences
AU3289199A (en) 1998-02-11 1999-08-30 Maxygen, Inc. Antigen library immunization
AU2674299A (en) 1998-02-11 1999-08-30 Maxygen, Inc. Targeting of genetic vaccine vectors
JP4700805B2 (ja) 1998-06-29 2011-06-15 ブリストル−マイヤーズ スクウィブ カンパニー 多様性の高いライブラリーを製造する方法
FR2782323B1 (fr) 1998-08-12 2002-01-11 Proteus Procede de production in vitro de sequences polynucleotidiques recombinees, banques de sequences et sequences ainsi obtenues
JP2002537758A (ja) 1998-09-29 2002-11-12 マキシジェン， インコーポレイテッド コドン変更された遺伝子のシャッフリング
WO2000020573A2 (fr) 1998-10-07 2000-04-13 Maxygen, Inc. Rearrangement d'adn pour produire des acides nucleiques de detoxication contre les mycotoxines
AU2415200A (en) 1999-01-18 2000-08-01 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
IL137868A0 (en) 1999-01-19 2001-10-31 Maxygen Inc Oligonucleotide mediated nucleic acid recombination
WO2001029211A2 (fr) 1999-10-19 2001-04-26 Enchira Biotechnology Corporation Technique relative a une evolution dirigee par generation aleatoire de chimeres sur des matrices transitoires
WO2001029212A1 (fr) 1999-10-19 2001-04-26 Enchira Biotechnology Corporation Procede de genese de chimeres de genomes entiers ou de polynucleotides de grande taille
WO2003078583A2 (fr) 2002-03-09 2003-09-25 Maxygen, Inc. Optimisation de points de croisement a des fins d'evolution dirigee

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US6323030B1 (en) 1994-02-17 2001-11-27 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6518065B1 (en) 1994-02-17 2003-02-11 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5741691A (en) 1996-01-23 1998-04-21 California Institute Of Technology Para-nitrobenzyl esterases with enhanced activity in aqueous and nonaqueous media
US6107073A (en) 1996-03-19 2000-08-22 Leukosite, Inc. Kinase capable of site-specific phosphorylation of IκBα
US6109776A (en) 1998-04-21 2000-08-29 Gene Logic, Inc. Method and system for computationally identifying clusters within a set of sequences
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
WO2001075767A2 (fr) 2000-03-30 2001-10-11 Maxygen, Inc. Selection de sites de recombinaison par enjambement in silico
WO2001090346A2 (fr) 2000-05-23 2001-11-29 California Institute Of Technology Recombinaison de genes et mise au point de proteines hybrides
US20020045175A1 (en) * 2000-05-23 2002-04-18 Zhen-Gang Wang Gene recombination and hybrid protein development
US20030032059A1 (en) 2000-05-23 2003-02-13 Zhen-Gang Wang Gene recombination and hybrid protein development
WO2003055978A2 (fr) 2001-10-26 2003-07-10 California Institute Of Technology Recombinaison de genes et developpement de proteines hybrides

Non-Patent Citations (89)

* Cited by examiner, † Cited by third party
Title
A.M. ter Laak et al., "Modelling and mutation studies on the histamine H1-receptor agonist binding site reveal different binding modes for H1-agonists: Asp116 (TM3) has a constitutive role in receptor stimulation", Journal of Computer Aided Molecular Design, vol. 9 (1995) pp. 319-330). *
Abkevich et al., "Impact of Local and Non-Local Interactions on Thermodynamics and Kinetics of Protein Folding," J. Mol. Biol., 252: 460-471, 1995.
Accelrys Website, GCG Wisconsin Package, 15 Pages, 2002.
Aita et al., "Theory of Evolutionary Molecular Engineering Through Simultaneous Accumulation of Advantageous Mutations," J. Theor. Biol., 207:543-556, 2000.
Arnold, "Combinatorial and Computational Challenges for Biocatalyst design", Nature, 2001, 409(6817):253-257.
Backofen et al., "Application of Constraint Programming Techniques for Structure Prediction of Lattice Proteins with Extended Alphabets," Bioinformatics, vol. 15, No. 3, 234-242 (1999).
Bahar et al., "Inter-residue Potentials in Globular Proteins and the Dominance of Highly Specific Hydrophilic Interactions at Close Separation," J. Mol. Biol., 266, 195-214 (1997).
Betancourt et al., "Pair Potentials for Protein Folding: Choice of Reference States and Sensitivity of Predicted Native States to Variations in the Interaction Schemes," Protein Science, 8: 361-369 (1999).
Boder et al., "Directed Evolution of Antibody Fragments with Monovalent Femtomolar Antigen binding Affinity", Proc. Natl. Acad. Sci. USA, 2000 97 (20):10701-10705.
Bohm, "New approaches in molecular structure prediction", Biophys Chem., 1996, 59: 1-32.
Buchler et al., "Effect of Alphabet Size and Foldability Requirements on Protein Structure Designability," Proteins: Structure, Function and Genetics 34:113-124 (1999).
Chao Zhang, "Extracting Contact Energies From Protein Structures: A Study Using a Simplified Model," Proteins: Structure, Function, and Genetics, 31:299-308 (1998).
Chen & Arnold, F.H., "Tuning the Activity of an Enzyme for Unusual Environments: Sequential Random Mutagenesis of Subtilisin E for Catalysis in Dimethyyformamide", Proc. Natl. Acad. Sci. U.S.A. 1993, 90:5618-5622.
Chen et al., "Tuning the Activity of an Enzyme for Unusual Environments: Sequential Random Mutagenesis of Substilisin E for Catalysis in Dimethylformamide," Proc. Natl. Acad. Sci. USA, vol. 90, pp. 5618-5622, 1993.
D.K. Agrafiotis, "Multiobjective Optimization of Combinatorial Libraries," IBM J. Res & Dev., vol. 45, No. 3, 545-566, 2001.
Dandekar et al., "Applying experimental data to protein fold prediction with the genetic algorithm," Protein Engineering, vol. 10, (1997) pp. 877-893. *
De Maeyer et al., "All in One: A Highly Detailed Roamer Library Improves Both Accuracy and Speed in the Modeling of Sidechains by Dead-End Elimination", Folding & Design, 1997, 2, 53-66.
Desjarlais & Clarke N.D., "Computer Search Algorithms in Protein Modification and Design," Curr. Opin. Struct. Biol., 1998, 8:471-475.
Dube et al., "Selection of New Biologically Active Molecules from Random Nucleotide Sequences," Gene 1993, 137:41-47.
Dunbrack & Karplus, "Conformational Analysis of the Backbone-Dependent Roamer Preferences of Protein Sidechains," Nature Struct. Bio/. 1994, 1:334-340.
Dunbrack & Karplus, M., "Backbone-Dependent Rotamer Library for Proteins Application to Sidechain Prediction," J. Mol. Biol. 1993, 230:543-574.
Eroshkin et al., "Algorithm and computer program Pro-Anal for analysis of relationship between structure and activity in a family of proteins or peptides," CABIOS, vol. 9, No. 5, 1993, pp. 491-497.
Eroshkin et al., "Proanal version 2: multifunctional program for analysis of multiple protein sequence alignments and for studying the structure-activity relationships in protein families," CABIOS, vol. 11, No. 1, 1995, pp. 39-44.
European Search Report dated Oct. 12, 2006 from related European Application No. 03711540.9-2201 PCT/US0307610.
Fetrow et al ., "New program for Protein Tertiary Structure Prediction," Biotechnol., 1993, 11(4):479-484.
Flickinger et al., "Enzymes, Directed Evolution", in 2 Encyclopedia of Bioprocess Technology: Fermentation, Biocatalysis, and Bioseparation 1999, 2:971-987.
Fontana & Shuster, "Continuity in Evolution: On the Nature of Transitions," Science 1998, 280:1451-1455.
Foote et al., Breaking the Affinity Ceiling for Antibodies and T. Cell Receptors, Proc. National Academy Sci. USA, vol. 97, No. 20, Sep. 26, 2000, pp. 10679-10681.
Friesner et al., "Computer Simulation of Protein Folding," printed from http://www.chem.columbia.edu/cbs/protein/annrev/txt.html on Feb. 27, 2001, 15 Pages.
Gan et al., "Lattice Protein Folding with Two and Four-Body Statistical Potentials," Proteins: Structure, Function and Genetics 43:161-174 (2001).
Geladi et al., "Partial Least Squares Regression: A Tutorial," Anal Chim Acta, 168: 1-17, 1986.
Giver et al, "Directed evolution of a Thermostable Esterase," Proc. Nat!. Acad. Sci., USA 1998, 95:12809-12813.
Godzik, "In Search of the Ideal Protein Sequence," Protein Engineering, 1995, 8:409-416.
Hogue et al., "Structure Databases," Methods Biochem. Anal. 1998, 39:46-73.
Holler et al., "In Vitro evolution of a T Cell Receptor with High Affinity for Peptide /MHC", Proc. National Academy Sci. USA, vol. 97, No. 10, May 9, 2000, pp. 5387-5392.
Holowachuk et al., "Efficient Gene Synthesis by Klenow Assembly/Extension-Pfu Polymerase Amplification (KAPPA) of Overlapping Olingonucleotides," PCR Methods Appl, 4:299-302, 1995.
Ivanisenko et al., "Search for Sites with Functionally Important Substitutions in Sets of Related or Mutant Protein," Biopolymer Physics and Physical Chemistry, Molecular Biology, vol. 31, No. 5, 1997, pp. 749-755.
Jain et al., "The Crystal Structure of an Autoprocessed Ser221 Cys-subtilisin E-propeptide Complexat 2.0 A Resolution," Mol. Biol. 1998, 284:137-144.
Jan Drenth, Principles of Protein X-Ray Crystallography, Springer-Verlag, pp. 12-18, 1995.
Johnson et al., "The Traveling Salesman Problem: A Case Study in Local Optimization," In Local Search in Combinatorial Optimization, Edited by Aarts et al., John Wiley & Sons Ltd., 21-310, 1997.
Jonathan King, "Unexpected Pathways to Protein Stabilization", Nature Biotechnology, vol. 14, Apr. 1996.
Joo et al., "Laboratory Evolution of Peroxide-Mediated Cytochrome P450 Hydroxylation.," Nature 1999, 399:670-672.
Kay, "NMR Methods for the Study of Protein Structure and Dynamics," Biochem. Cell Biol., 1997, 75:1-1 5 (1997).
Koehl & Delarue, "Application of a Self-consistent Mean Field Theory to Predict Protein Side-chains Conformation and Estimate Their Conformational Entropy", J. Mol. Bioi. 1994, 239:249-275.
Koehl & Delarue, Mean-field Minimization Methods for Biological Macromolecules Curr. Opin. In Struct. Biol. 1996, 6:222-226.
König et al. "Refined Genetic Algorithm Simulations to Model Proteins" , Journal of Molecular Modeling, vol. 5 (1999), pp. 317-324. *
Lazar, "De Novo Design of the Hydrophobic Core of Ubiquitin," Protein Science, 1997, 6: 1167-1178.
Lee & Richards, "The Interpretation of Protein Structures: Estimation of Static Accessibility," J. Mol. Biol., 1971, 55: 379-400.
Lee & Subbiah "Prediction of Protein Side-chain Conformation by Packing Optimization," J. Mol. Biol., 1991, 217,373-388.
Lee, "Predicting Protein Mutant Energetics by Self-consistent Ensemble Optimization," J. Mol. Biol., 1994, 236:918-939.
Levitt et al., "Protein folding: The endgame," Annu. Rev. Biochem., 1997, 66:549-579.
Lewis Ricki, The Scientist, pp. 1-4, 1993.
Li et al., "Emergence of Preferred Structures in a Simple Model of Protein Folding," Science 1996, 273:666-669.
Li et al., "Nature of Driving Force for Protein Folding: A Result from Analyzing the Statistical Potential," The American Physical Society, vol. 79, No. 4, 765-768 (1997).
M. Ostwemeier et al., "A Combinatorial Approach to Hybrid Enzymes Independent of DNA Homology," Nature Biotechnology, vol. 17, pp. 1205-1209, 1999.
Martin et al., "Measuring Diversity: Experimental Design of Combinatorial Libraries for Drug Discovery," J. Med. Chem. 38, 1431-1436, 1995.
Matsumura et al., "Structural Studies of Mutants of T4 Lysozyme That Alter Hydrophobic Stabilization," J. Biol. Chem. 1989, 264:16059-16066.
Miyazaki & Arnold, "Directed Evolution Study of Temperature Adaptation in a Psychrophilic Enzyme," J.MoI. Biol. 2000, 297:1015-1026.
Miyazaki & Arnold, "Exploring Nonnatural Evolutionary Pathways by Saturation Mutagenesis: Rapid Improvement of Protein Function," J. Molecular Evolution, 1999, 49:716-720.
Miyazawa et al., "An Empirical Energy Potential With a References State for Protein Fold and Sequence Recognition," Proteins: Structure, Function, and Genetics, 36:357-369 (1999).
Miyazawa et al., "Residue-Residue Potentials with a Favorable Contact Pair Term and an Unfavorable High Packing Density Term, for Simulation and Threading," J. Mol. Biol., 256:623-644 (1996).
Miyazawa et al., "Self-Consistent Estimation of Inter-Residue Protein Contact Engergies Based on an Equilibrium Mixture Approximation of Residues," Proteins: Structure, Function, and Genetics, 34:49-68 (1999).
Moore & Arnold, "Directed Evolution of a Para-nitrobenzyl esterase for aqueous-organic Solvents," Nature Biotechnology, 1996, 14(4):458.
Mundorff et al., "In silico DNA Shuffling," Manuscript submitted to Nature Structural Biology, 23 Pages (1994).
Nikolova et al., "Semirational Design of Active Tumor Suppressor P53 DNA Binding Domain with Enhanced Stability," Proc. Natl. Acad. Sci. U.S.A. 1998, 95:14675-14680.
Park, "Toward an Energy Function for the Contact Map Representation of Proteins," Proteins: Structure, Function and Genetics 40:237-248 (2000).
Peter Halling, "Is Random Mutation More Rational", Nature Biotechnology, vol. 14, Apr. 1996.
Pjura et al, "Development of an in vivo Method to Identify Mutants of Phage T4 lysozyme of Enhanced Thermostability," Protein Science 1993, 2:2217-2225 .
Richards et al., "Advances in Protein Chemistry," Adv. Protein Chem., 55:ix-xi, 2000.
Robert F. Service, "Tapping DNA for Structures Produces a Trickle," News Focus, Science, vol. 298, pp. 948-950, 2002.
Roger Sheldon, "Picking a Winner", Nature, vol. 399, Jun. 17, 1999, pp. 636-637.
Sasai, "Conformation, Energy, and Folding Ability of Selected Amino Acid Sequences," Proc. Natl. Acad. Sci. USA, 1995, 92: 8438-8442.
Saven & Wolynes, "Statistical Mechanics of the Combinatorial Synthesis and Analysis of Folding Macromolecules," J. Phys. Chem. B. 1997, 101:8375-8389.
Sheridan et al., "Using a Genetic Algorithm to Suggest Combinatorial Libraries," J. Chem. Inf. Compu. Sci., 35, 310-320, 1995.
Singh et al., "Application of Genetic Algorithms to Combinatorial Synthesis: A Computational Approach to Lead Identification and Lead Optimization," J. Am. Chem. Soc. 118, 1669-1676 (1996).
Skandalis et a/., "Creating Novel Enzymes by Applied Molecular Evolution," Chem. Biol. 1997, 4:889-898.
Skorobogatiy et al., "An Analytical Approach to Protein Design," printed from website http://www.netsci-journal.com/97v2/25.htm on Dec. 17, 2001-Abstract.
Skorobogatiy et al., "Mapping of Mutation-Sensitive Sites in Proteinlike Chains," The American Physical Society, vol. 58, No. 3: 3572-2577 (1998).
Stemmer, WPC, "Rapid Evolution of a Protein in Vitro by DNA Shuffling", Nature, Aug. 4, 1994, vol. 370, pp. 389-391.
U.S. Office Action mailed Mar. 13, 2006, from U.S. Appl. No. 10/379,378.
U.S. Office Action mailed Sep. 28, 2006, from U.S. Appl. No. 10/379,378.
Voigt et al., "Calculating the Crossover Points for Gene Recombination and Hybrid Protein Creation," U.S. Appl. No. 60/201,048, filed May 23, 2000, 28 Pages.
Voigt et al., "Computationally Focusing the Directed Evolution of Proteins," Journal of Cellular Biochemistry Supplement, 37:58-63 (2001).
Whitlow, "1.85 A structure of Anti-Fluorescein 4-4-20 Fab," Protein Engineering, 1995, 8:749-761.
Wilson et al., "Modeling Side-chain Conformation for Homologous Proteins Using an Energy-Based Rotomer Search," J. Mol. Biol. 1993, 229:996-1006.
Wuthrich, "NMR-This Other Method for Protein and Nucleic Acid Structure Determination," Acta Cyrstallogr., 1995, D51:249-270.
You & Arnold, "Directed Evolution of Subtilisin E in Bacillus Subtilis to Enhance Total Activity in Aqueous Dimethylformamide", Protein Engineering 1994, 9(1):77-83.
Zhao & Arnold, "Directed Evolution Converts Subtilisin E into a Functional Equivalent of Thermitase," Protein Engineering 1999, 12(1):47-53.
Zhao & Arnold, "Optimization of DNA shuffling for High Fidelity Recombination," Nuci. Acids Res., 1997, 25(6):1307-1308.

Cited By (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8224580B2 (en) 2002-03-09 2012-07-17 Codexis Mayflower Holdings Llc Optimization of crossover points for directed evolution
US20100070192A1 (en) * 2002-03-09 2010-03-18 Maxygen, Inc. Optimization of crossover points for directed evolution
US8108150B2 (en) 2002-03-09 2012-01-31 Codexis Mayflower Holdings, Llc Optimization of crossover points for directed evolution
US20080020397A1 (en) * 2002-03-09 2008-01-24 Maxygen, Inc. Optimization of crossover points for directed evolution
WO2012024698A1 (fr) 2010-08-20 2012-02-23 Codexis, Inc. Utilisation de protéines de la famille 61 des glycoside hydrolases dans le traitement de la cellulose
US9493802B2 (en) 2010-08-20 2016-11-15 Codexis, Inc. Use of glycohydrolase 61 protein variants with improved thermostability for processing cellulose
US8877474B2 (en) 2010-08-20 2014-11-04 Codexis, Inc. GH61 glycoside hydrolase protein variants and cofactors that enhance GH61 activity
US9322027B2 (en) 2010-08-20 2016-04-26 Shell Oil Company Expression constructs comprising fungal promoters
US8663962B2 (en) 2011-03-30 2014-03-04 Codexis, Inc. Pentose fermentation by a recombinant microorganism
US9169468B2 (en) 2011-03-30 2015-10-27 Codexis, Inc. Pentose fermentation by a recombinant microorganism
US9045745B2 (en) 2011-06-30 2015-06-02 Codexis, Inc. Pentose fermentation by a recombinant microorganism
US8778652B2 (en) 2011-06-30 2014-07-15 Codexis, Inc. Pentose fermentation by a recombinant microorganism
WO2013028701A1 (fr) 2011-08-22 2013-02-28 Codexis, Inc. Variants protéiques des glycosides hydrolases gh61 et cofacteurs renforçant l'activité des gh61
US8951758B2 (en) 2011-08-22 2015-02-10 Codexis, Inc. GH61 glycoside hydrolase protein variants and cofactors that enhance GH61 activity
US9434919B2 (en) 2011-09-30 2016-09-06 Codexis, Inc. Fungal proteases
US9611462B2 (en) 2011-12-20 2017-04-04 Codexis, Inc. Endoglucanase 1B (EG1B) variants
US8956844B2 (en) 2012-06-11 2015-02-17 Codexis, Inc. Fungal xylanases and xylosidases
US8980578B2 (en) 2012-06-11 2015-03-17 Codexis, Inc. Fungal beta-xylosidase variants
WO2013188305A2 (fr) 2012-06-11 2013-12-19 Codexis, Inc. Variants de la beta-xylosidase fongique
US9476077B2 (en) 2012-06-11 2016-10-25 Codexis, Inc. Fungal beta-xylosidase variants
US9611515B2 (en) 2012-11-20 2017-04-04 Codexis, Inc. Pentose fermentation by a recombinant microorganism
US9611468B2 (en) 2013-04-18 2017-04-04 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
US10870843B2 (en) 2013-04-18 2020-12-22 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
US10487319B2 (en) 2013-04-18 2019-11-26 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
US11136571B2 (en) 2013-04-18 2021-10-05 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
WO2014172541A2 (fr) 2013-04-18 2014-10-23 Codexis, Inc. Polypeptides de phénylalanine ammoniac-lyase modifiés
US10494623B2 (en) 2013-04-18 2019-12-03 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
EP3521423A1 (fr) 2013-04-18 2019-08-07 Codexis, Inc. Polypeptides de phénylalanine ammoniaque lyase modifiés
US10640759B2 (en) 2013-04-18 2020-05-05 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
US11401515B2 (en) 2013-04-18 2022-08-02 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
US11130947B2 (en) 2013-04-18 2021-09-28 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
US10358639B2 (en) 2013-04-18 2019-07-23 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
US10294468B2 (en) 2013-04-18 2019-05-21 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
US10975367B2 (en) 2013-04-18 2021-04-13 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
EP3971288A1 (fr) 2013-04-18 2022-03-23 Codexis, Inc. Polypeptides de phénylalanine ammoniaque lyase modifiés
US10941391B2 (en) 2013-04-18 2021-03-09 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
US11913045B2 (en) 2013-04-18 2024-02-27 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
US10717974B2 (en) 2013-04-18 2020-07-21 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
US10160963B2 (en) 2013-04-18 2018-12-25 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
US10144924B2 (en) 2013-04-18 2018-12-04 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
EP3418929A1 (fr) 2013-09-27 2018-12-26 Codexis, Inc. Sélection automatique de variantes enzymatiques
US9822346B2 (en) 2013-11-13 2017-11-21 Codexis, Inc. Engineered imine reductases and methods for the reductive amination of ketone and amine compounds
WO2015073555A1 (fr) 2013-11-13 2015-05-21 Codexis, Inc. Imines réductases manipulées et procédés d'amination réductrice de composés cétoniques et aminés
US11060072B2 (en) 2013-11-13 2021-07-13 Codexis, Inc. Engineered imine reductases and methods for the reductive amination of ketone and amine compounds
US10407668B2 (en) 2013-11-13 2019-09-10 Codexis, Inc. Engineered imine reductases and methods for the reductive amination of ketone and amine compounds
EP3928787A1 (fr) 2014-04-16 2021-12-29 Codexis, Inc. Tyrosine ammoniac-lyase génétiquement modifiée
US10533168B2 (en) 2014-04-16 2020-01-14 Codexis, Inc. Engineered tyrosine ammonia lyase
US11015184B2 (en) 2014-04-16 2021-05-25 Codexis, Inc. Polynucleotides encoding engineered tyrosine ammonia lyase variants
US10287567B2 (en) 2014-04-16 2019-05-14 Codexis, Inc. Polynucleotides encoding engineered tyrosine ammonia lyase variants
US9605252B2 (en) 2014-04-16 2017-03-28 Codexis, Inc. Engineered tyrosine ammonia lyase
WO2015161019A1 (fr) 2014-04-16 2015-10-22 Codexis, Inc. Tyrosine ammonia-lyase génétiquement modifiée
US9708587B2 (en) 2014-07-09 2017-07-18 Codexis, Inc. P450-BM3 variants with improved activity
US10100289B2 (en) 2014-07-09 2018-10-16 Codexis, Inc. P450-BM3 variants with improved activity
US11279917B2 (en) 2014-07-09 2022-03-22 Codexis, Inc. P450-BM3 variants with improved activity
US10689627B2 (en) 2014-07-09 2020-06-23 Codexis, Inc. P450-BM3 variants with improved activity
US11807874B2 (en) 2014-07-09 2023-11-07 Codexis, Inc. P450-BM3 variants with improved activity
US10370648B2 (en) 2014-11-25 2019-08-06 Codexis, Inc. Engineered imine reductases and methods for the reductive amination of ketone and amine compounds
WO2016085916A1 (fr) 2014-11-25 2016-06-02 Codexis, Inc. Imines réductases génétiquement modifiées et procédés d'amination réductrice de composés cétoniques et aminés
US10793836B2 (en) 2014-11-25 2020-10-06 Codexis, Inc. Engineered imine reductases and methods for the reductive amination of ketone and amine compounds
US11352609B2 (en) 2014-11-25 2022-06-07 Codexis, Inc. Engineered imine reductases and methods for the reductive amination of ketone and amine compounds
US11802274B2 (en) 2014-11-25 2023-10-31 Codexis, Inc. Engineered imine reductases and methods for the reductive amination of ketone and amine compounds
WO2016105889A1 (fr) 2014-12-22 2016-06-30 Codexis, Inc. Variants d'alpha-galactosidase humaine
US11278600B2 (en) 2014-12-22 2022-03-22 Codexis, Inc. Human alpha-galactosidase variants
US11497798B2 (en) 2014-12-22 2022-11-15 Codexis, Inc. Human alpha-galactosidase variants
US10973888B2 (en) 2014-12-22 2021-04-13 Codexis, Inc. Human alpha-galactosidase variants
WO2016130412A1 (fr) 2015-02-10 2016-08-18 Codexis, Inc. Polypeptides de cétoréductase pour la synthèse de composés chiraux
US11236308B2 (en) 2015-02-10 2022-02-01 Codexis, Inc. Ketoreductase polypeptides for the synthesis of chiral compounds
US10696953B2 (en) 2015-02-10 2020-06-30 Codexis, Inc. Ketoreductase polypeptides for the synthesis of chiral compounds
US9944916B2 (en) 2015-05-07 2018-04-17 Codexis, Inc. Penicillin-G acylases
US10400231B2 (en) 2015-05-07 2019-09-03 Codexis, Inc. Penicillin-G acylases
WO2016179464A1 (fr) 2015-05-07 2016-11-10 Codexis, Inc. Pénicilline g acylases
US10781436B2 (en) 2015-05-07 2020-09-22 Codexis, Inc. Penicillin-G acylases
US11180747B2 (en) 2015-05-07 2021-11-23 Codexis, Inc. Variant penicillin-G acylases
WO2017007547A1 (fr) 2015-07-07 2017-01-12 Codexis, Inc. Nouveaux variants de p450-bm3 ayant une activité améliorée
US10113153B2 (en) 2015-07-07 2018-10-30 Codexis, Inc. P450-BM3 variants with improved activity
US11591578B2 (en) 2015-07-07 2023-02-28 Codexis, Inc. P450-BM3 variants with improved activity
US10704030B2 (en) 2015-07-07 2020-07-07 Codexis, Inc. P450-BM3 variants with improved activity
US10450550B2 (en) 2015-07-07 2019-10-22 Codexis, Inc. P450-BM3 variants with improved activity
US10982197B2 (en) 2015-07-07 2021-04-20 Codexis, Inc. P450-BM3 variants with improved activity
US9683220B2 (en) 2015-07-07 2017-06-20 Codexis, Inc. P450-BM3 variants with improved activity
US10724025B2 (en) 2016-05-05 2020-07-28 Codexis, Inc. Penicillin-G acylases
US11214786B2 (en) 2016-05-05 2022-01-04 Codexis, Inc. Penicillin-G acylases
WO2017193022A1 (fr) 2016-05-05 2017-11-09 Codexis, Inc. Pénicilline g acylases
US11965192B2 (en) 2016-05-05 2024-04-23 Codexis, Inc. Penicillin-G acylases
US10844358B2 (en) 2016-06-09 2020-11-24 Codexis, Inc. Polynucleotides encoding biocatalysts and methods for hydroxylation of chemical compounds
US11634695B2 (en) 2016-06-09 2023-04-25 Codexis, Inc. Vectors for expression of biocatalysts
WO2017213758A1 (fr) 2016-06-09 2017-12-14 Codexis, Inc. Biocatalyseurs et procédés d'hydroxylation de composés chimiques
US10184117B2 (en) 2016-06-09 2019-01-22 Codexis, Inc. Biocatalysts and methods for hydroxylation of chemical compounds
US11299723B2 (en) 2016-06-15 2022-04-12 Codexis, Inc. Engineered beta-glucosidases and glucosylation methods
EP4223766A2 (fr) 2016-08-26 2023-08-09 Codexis, Inc. Imine réductases modifiées et procédés d'amination réductrice de composés cétoniques et aminés
WO2018038906A1 (fr) 2016-08-26 2018-03-01 Codexis, Inc. Imines réductases manipulées et procédés d'amination réductrice de composés cétoniques et aminés
US11046936B2 (en) 2016-08-26 2021-06-29 Codexis, Inc. Engineered imine reductases and methods for the reductive amination of ketone and amine compounds
US11591588B2 (en) 2017-01-05 2023-02-28 Codexis, Inc. Penicillin-G acylases
US10745681B2 (en) 2017-01-05 2020-08-18 Codexis, Inc. Penicillin-G acylases
US10865402B2 (en) 2017-01-05 2020-12-15 Codexis, Inc. Penicillin-G acylases
WO2018144679A2 (fr) 2017-02-03 2018-08-09 Codexis, Inc. Glycosyl transférases modifiées et procédés de glucosylation de glycosides de stéviol
US11920167B2 (en) 2017-02-03 2024-03-05 Tate & Lyle Solutions Usa Llc Engineered glycosyltransferases and steviol glycoside glucosylation methods
US10995329B2 (en) 2017-02-13 2021-05-04 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
US11021729B2 (en) 2017-04-27 2021-06-01 Codexis, Inc. Ketoreductase polypeptides and polynucleotides
US11746369B2 (en) 2017-04-27 2023-09-05 Codexis, Inc. Ketoreductase polypeptides and polynucleotides
EP3957723A2 (fr) 2017-05-08 2022-02-23 Codexis, Inc. Variants de ligase modifiés
WO2018208665A1 (fr) 2017-05-08 2018-11-15 Codexis, Inc. Variants de ligase modifiés
US11359183B2 (en) 2017-06-14 2022-06-14 Codexis, Inc. Engineered transaminase polypeptides for industrial biocatalysis
US11643642B2 (en) 2017-06-27 2023-05-09 Codexis, Inc. Penicillin-g acylases
US10738286B2 (en) 2017-06-30 2020-08-11 Codexis, Inc. T7 RNA polymerase variants
US10793841B2 (en) 2017-06-30 2020-10-06 Codexis, Inc. T7 RNA polymerase variants
US11236311B2 (en) 2017-06-30 2022-02-01 Codexis, Inc. T7 RNA polymerase variants
US11236312B2 (en) 2017-06-30 2022-02-01 Codexis, Inc. T7 RNA polymerase variants
US11319531B2 (en) 2017-11-07 2022-05-03 Codexis, Inc. Transglutaminase variants
US11015180B2 (en) 2017-12-13 2021-05-25 Codexis, Inc. Carboxyesterase polypeptides for amide coupling
US11421253B2 (en) 2018-06-12 2022-08-23 Codexis, Inc. Engineered tyrosine ammonia lyase
US10900055B2 (en) 2018-06-12 2021-01-26 Codexis, Inc. Engineered tyrosine ammonia lyase
US11162105B2 (en) 2018-07-09 2021-11-02 Codexis, Inc. Engineered purine nucleoside phosphorylase variant enzymes
US11466259B2 (en) 2018-07-09 2022-10-11 Codexis, Inc. Engineered galactose oxidase variant enzymes
US11274286B2 (en) 2018-07-09 2022-03-15 Codexis, Inc. Engineered deoxyribose-phosphate aldolases
US11034948B2 (en) 2018-07-09 2021-06-15 Codexis, Inc. Engineered phosphopentomutase variant enzymes
US11845968B2 (en) 2018-07-09 2023-12-19 Codexis, Inc. Engineered deoxyribose-phosphate aldolases
US11795445B2 (en) 2018-07-09 2023-10-24 Codexis, Inc. Engineered phosphopentomutase variant enzymes
US10889806B2 (en) 2018-07-09 2021-01-12 Codexis, Inc. Engineered pantothenate kinase variant enzymes
US11198861B2 (en) 2018-07-12 2021-12-14 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
US11760981B2 (en) 2018-07-30 2023-09-19 Codexis, Inc. Engineered glycosyltransferases and steviol glycoside glucosylation methods
US11060075B2 (en) 2018-10-29 2021-07-13 Codexis, Inc. Engineered DNA polymerase variants
US11473077B2 (en) 2018-12-14 2022-10-18 Codexis, Inc. Engineered tyrosine ammonia lyase
US11427813B2 (en) 2018-12-20 2022-08-30 Codexis, Inc. Human alpha-galactosidase variants
US11970722B2 (en) 2019-12-20 2024-04-30 Codexis, Inc. Engineered acid alpha-glucosidase variants
US11788071B2 (en) 2020-04-10 2023-10-17 Codexis, Inc. Engineered transaminase polypeptides
US11767519B2 (en) 2020-08-28 2023-09-26 Codexis, Inc. Engineered amylase variants
US11959108B2 (en) 2020-08-28 2024-04-16 Codexis, Inc. Engineered protease variants
US11898174B2 (en) 2020-12-18 2024-02-13 Codexis, Inc. Engineered uridine phosphorylase variant enzymes
US11913037B2 (en) 2021-04-02 2024-02-27 Codexis, Inc. Engineered adenylate kinase variant enzymes
WO2022212835A1 (fr) 2021-04-02 2022-10-06 Codexis, Inc. Enzymes variantes d'acétate kinase modifiées
US11913036B2 (en) 2021-04-02 2024-02-27 Codexis, Inc. Engineered acetate kinase variant enzymes
WO2022212832A1 (fr) 2021-04-02 2022-10-06 Codexis, Inc. Enzymes variantes de la gmp-amp synthase (cgaz) cyclique génétiquement modifiées
WO2022212828A1 (fr) 2021-04-02 2022-10-06 Codexis, Inc. Enzymes variantes de guanylate kinase modifiées
WO2022212824A1 (fr) 2021-04-02 2022-10-06 Codexis, Inc. Enzymes variants de d'adénylate kinase modifiées
WO2024040020A1 (fr) 2022-08-15 2024-02-22 Absci Corporation Enrichissement de cellule spécifique à une activité d'affinité quantitative

Also Published As

Publication number Publication date
AU2003213846A8 (en) 2003-09-29
US20100070192A1 (en) 2010-03-18
EP1488335A4 (fr) 2006-11-15
WO2003078583A3 (fr) 2004-03-18
US20080020397A1 (en) 2008-01-24
US20030198988A1 (en) 2003-10-23
JP2010015581A (ja) 2010-01-21
US8224580B2 (en) 2012-07-17
WO2003078583A2 (fr) 2003-09-25
JP2011217751A (ja) 2011-11-04
JP2005520244A (ja) 2005-07-07
US8108150B2 (en) 2012-01-31
JP4851687B2 (ja) 2012-01-11
AU2003213846A1 (en) 2003-09-29
EP1488335A2 (fr) 2004-12-22

Similar Documents

Publication Publication Date Title
US7620500B2 (en) Optimization of crossover points for directed evolution
US11342046B2 (en) Methods and systems for engineering biomolecules
JP5319865B2 (ja) 機能的生体分子を同定する方法、システム、およびソフトウェア
EP2250594B1 (fr) Procédé de génération d'une population diversifiée optimisée de variants
US20020045175A1 (en) Gene recombination and hybrid protein development
WO2001075767A2 (fr) Selection de sites de recombinaison par enjambement in silico
Rost Prediction in 1D: secondary structure, membrane helices, and accessibility
WO2001061344A1 (fr) Conception evolutive a ciblage computationnel
Kimura et al. Hyperstable de novo protein with a dimeric bisecting topology
US20030032059A1 (en) Gene recombination and hybrid protein development
WO2003091835A2 (fr) Conception evolutive a ciblage informatique
WO2008127213A2 (fr) Procédés, systèmes et logiciel pour recombinaison régulée, induite par des oligonucléotides
US20150269308A1 (en) Engineering surface epitopes to improve protein crystallization
DK2250594T3 (en) Process for generating an optimized, diverse population of variants
SCHRAG 14 Structure Information
Albou et al. ILLUSTRATED ABSTRACT TABLE OF CONTENTS
Stark Functional Sites in Structure and Sequence. Protein Active Sites and miRNA Target Recognition
Wang et al. 7 Comparative Modeling
Wang et al. 7 Comparative Modeling and Structural Proteomics

Legal Events

Date Code Title Description
AS Assignment

Owner name: MAXYGEN, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MUNDORFF, EMILY C.;GOVINDARAJAN, SRIDHAR;GUSTAFSSON, CLAES;AND OTHERS;REEL/FRAME:014208/0763;SIGNING DATES FROM 20030602 TO 20030610

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
AS Assignment

Owner name: CODEXIS MAYFLOWER HOLDINGS, LLC, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MAXYGEN, INC.;REEL/FRAME:025443/0641

Effective date: 20101028

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 12

AS Assignment

Owner name: CODEXIS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CODEXIS MAYFLOWER HOLDINGS, LLC;REEL/FRAME:066522/0143

Effective date: 20240206

AS Assignment

Owner name: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT, NEW YORK

Free format text: SECURITY INTEREST;ASSIGNOR:CODEXIS, INC.;REEL/FRAME:066600/0650

Effective date: 20240213